vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»vsp-670Research ArticleНЕПРЕРЫВНОЕ ПРОФЕССИОНАЛЬНОЕ ОБРАЗОВАНИЕPROFESSIONAL DEVELOPMENTКлинические примеры антицитокиновой терапии у детей с болезнью КронаCLINICAL EXAMPLES OF ANTICYTOKINE TREATMENT OF CHILDREN WITH CROHN DISEASEВенедиктоваМ.М.VenediktovaM.M.ЦимбаловаЕ.Г.TsimbalovaE.G.neonatepearl@yandex.ruПотаповА.С.PotapovА.S.neonatepearl@yandex.ruScientific Center of Children’s Health RAMS, MoscowНаучный центр здоровья детей РАМН, МоскваScientific Center of Children’s Health RAMS, MoscowНаучный центр здоровья детей РАМН, Москва
Первый Московский государственный медицинский университет им. И.М. СеченоваScientific Center of Children’s Health RAMS, Moscow201116092011105Вопросы современной педиатрии74–80Copyright © Венедиктова М., Цимбалова Е., Потапов А., 20112011Венедиктова М., Цимбалова Е., Потапов А.Venediktova M., Tsimbalova E., Potapov А.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/670ReferencesМазанкова Л.Н., Халиф И.Л., Водилова О.В. Болезнь Крона у детей. Принципы диагностики и лечения. М.: МЕДпресс–информ. 2008.Мазанкова Л.Н., Халиф И.Л., Водилова О.В. Болезнь Крона у детей. Принципы диагностики и лечения. М.: МЕДпресс–информ. 2008.Sartor R.B. Pathogenesis ad immune mechanisms of chronic inflammatory bowel disease. Am. J. Gastroenterology. 1997; 92 (Suppl. 12): 533–589.Sartor R.B. Pathogenesis ad immune mechanisms of chronic inflammatory bowel disease. Am. J. Gastroenterology. 1997; 92 (Suppl. 12): 533–589.Scaldaferri F., Fiocchi C. Inflammatory bowel disease: Progress and current concepts of etiopathogenesis. J. Dig. Dis. 2007; 8: 171–178.Scaldaferri F., Fiocchi C. Inflammatory bowel disease: Progress and current concepts of etiopathogenesis. J. Dig. Dis. 2007; 8: 171–178.Papadakis K.A., Targan S.R. Role of cytokines in the pathogenesis of inflammatory bowel disease. Ann. Rev. Med. 2000; 51: 289–298.Papadakis K.A., Targan S.R. Role of cytokines in the pathogenesis of inflammatory bowel disease. Ann. Rev. Med. 2000; 51: 289–298.Breese E., Michie C., Nicholls S. et al. Tumor necrosis factor alpha producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology. 1994; 106; 1455–1466.Breese E., Michie C., Nicholls S. et al. Tumor necrosis factor alpha producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology. 1994; 106; 1455–1466.Белоусова Е.А., Моисеев С.В. Инфликсимаб: 10 лет успешного применения при воспалительных заболеваниях кишечника. Клиническая фармакология и терапия. 2010; 19 (1): 50–54.Белоусова Е.А., Моисеев С.В. Инфликсимаб: 10 лет успешного применения при воспалительных заболеваниях кишечника. Клиническая фармакология и терапия. 2010; 19 (1): 50–54.Targan S., Hanauer S., van Deventer S. et al. A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohns disease. N. Engl. J. Med. 1997; 337: 1029–1035.Targan S., Hanauer S., van Deventer S. et al. A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohns disease. N. Engl. J. Med. 1997; 337: 1029–1035.Hanauer S., Feagan B., Lichtenstein G. et al. Maintenance infliximab for Crohns disease: the ACCENT I randomized trial. Lancet. 2002; 359 (9317): 1541–1549.Hanauer S., Feagan B., Lichtenstein G. et al. Maintenance infliximab for Crohns disease: the ACCENT I randomized trial. Lancet. 2002; 359 (9317): 1541–1549.Bruce E., Sands M., Frank H. et al. Infliximab maintenance therapy for fistulizing Crohns disease. N. Engl. J. Med. 2004; 350: 876–885.Bruce E., Sands M., Frank H. et al. Infliximab maintenance therapy for fistulizing Crohns disease. N. Engl. J. Med. 2004; 350: 876–885.Hyams J., Crandall W., Kugathasan S. et al. Induction and maintenance infliximab therapy for the treatment of moderate to severe Crohns disease in children. Gastroenterology. 2006; 3.Hyams J., Crandall W., Kugathasan S. et al. Induction and maintenance infliximab therapy for the treatment of moderate to severe Crohns disease in children. Gastroenterology. 2006; 3.Colombel J., Rutgeerts P., Reinisch W. et al. SONIC: A randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohns disease naive to immunomodulators and biologic therapy. Gut. 2008; 57 (Suppl. II): 1.Colombel J., Rutgeerts P., Reinisch W. et al. SONIC: A randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohns disease naive to immunomodulators and biologic therapy. Gut. 2008; 57 (Suppl. II): 1.
The authors declare that there are no conflicts of interest present.